share_log

Modern Healthcare Technology Holdings Limited's (HKG:919) Price Is Right But Growth Is Lacking After Shares Rocket 32%

Modern Healthcare Technology Holdings Limited's (HKG:919) Price Is Right But Growth Is Lacking After Shares Rocket 32%

现代医疗科技控股有限公司(HKG:919)股价合理,但在股票火箭32%后增长乏力
Simply Wall St ·  2022/04/15 19:12

Modern Healthcare Technology Holdings Limited (HKG:919) shareholders are no doubt pleased to see that the share price has bounced 32% in the last month, although it is still struggling to make up recently lost ground. Notwithstanding the latest gain, the annual share price return of 5.5% isn't as impressive.

现代医疗科技控股有限公司(HKG:919)股东无疑很高兴看到股价在过去一个月反弹了32%,尽管它仍在努力收复最近的失地。尽管最近有所上涨,但5.5%的年度股价回报率并不令人印象深刻。

Although its price has surged higher, given close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") above 10x, you may still consider Modern Healthcare Technology Holdings as an attractive investment with its 6.8x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's limited.

尽管其股价飙升,但鉴于香港近一半的公司的市盈率(或“市盈率”)高于10倍,你可能仍会认为现代医疗科技控股公司的市盈率为6.8倍,是一项有吸引力的投资。尽管如此,仅仅以面值来看待市盈率是不明智的,因为可能会有一个解释为什么它是有限的。

For example, consider that Modern Healthcare Technology Holdings' financial performance has been poor lately as it's earnings have been in decline. One possibility is that the P/E is low because investors think the company won't do enough to avoid underperforming the broader market in the near future. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.

例如,考虑到现代医疗技术控股公司最近的财务表现一直很差,因为它的收益一直在下降。一种可能性是,市盈率较低是因为投资者认为该公司在不久的将来不会采取足够的措施来避免表现逊于大盘。如果你喜欢这家公司,你会希望情况并非如此,这样你就可以在它不再受青睐的时候买入一些股票。

Check out our latest analysis for Modern Healthcare Technology Holdings

查看我们对现代医疗技术控股公司的最新分析

SEHK:919 Price Based on Past Earnings April 15th 2022 Although there are no analyst estimates available for Modern Healthcare Technology Holdings, take a look at this free data-rich visualisation to see how the company stacks up on earnings, revenue and cash flow.
联交所:919价格基于过去收益2022年4月15日虽然没有分析师对现代医疗技术控股公司的估计,但请看一下这个免费的数据丰富的可视化图,看看该公司在收益、收入和现金流方面是如何堆积的。

Is There Any Growth For Modern Healthcare Technology Holdings?

现代医疗技术控股公司有增长吗?

The only time you'd be truly comfortable seeing a P/E as low as Modern Healthcare Technology Holdings' is when the company's growth is on track to lag the market.

只有当公司的增长落后于市场时,你才会真正放心地看到现代医疗技术控股公司的市盈率如此之低。

Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 38%. Unfortunately, that's brought it right back to where it started three years ago with EPS growth being virtually non-existent overall during that time. Therefore, it's fair to say that earnings growth has been inconsistent recently for the company.

首先回顾一下,该公司去年的每股收益增长并不令人兴奋,因为它公布了令人失望的38%的降幅。不幸的是,这让它回到了三年前的起点,在那段时间里,每股收益几乎没有增长。因此,公平地说,该公司最近的收益增长一直不一致。

This is in contrast to the rest of the market, which is expected to grow by 18% over the next year, materially higher than the company's recent medium-term annualised growth rates.

这与其他市场形成对比,后者预计明年将增长18%,大大高于该公司最近的中期年化增长率。

In light of this, it's understandable that Modern Healthcare Technology Holdings' P/E sits below the majority of other companies. It seems most investors are expecting to see the recent limited growth rates continue into the future and are only willing to pay a reduced amount for the stock.

有鉴于此,现代医疗技术控股公司的市盈率低于大多数其他公司也是可以理解的。似乎大多数投资者都预计,最近有限的增长率将持续到未来,他们只愿意为该股支付较低的价格。

What We Can Learn From Modern Healthcare Technology Holdings' P/E?

我们可以从现代医疗技术控股公司的市盈率中学到什么?

Modern Healthcare Technology Holdings' stock might have been given a solid boost, but its P/E certainly hasn't reached any great heights. It's argued the price-to-earnings ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.

现代医疗技术控股公司的股票可能得到了强劲的提振,但它的市盈率肯定没有达到任何很高的水平。有人认为,市盈率是衡量某些行业价值的次要指标,但它可以成为一个强大的商业信心指标。

As we suspected, our examination of Modern Healthcare Technology Holdings revealed its three-year earnings trends are contributing to its low P/E, given they look worse than current market expectations. Right now shareholders are accepting the low P/E as they concede future earnings probably won't provide any pleasant surprises. Unless the recent medium-term conditions improve, they will continue to form a barrier for the share price around these levels.

正如我们怀疑的那样,我们对现代医疗技术控股公司的调查显示,考虑到它们看起来比当前市场预期的更糟糕,它的三年收益趋势是导致其低市盈率的原因之一。目前,股东们正在接受低市盈率,因为他们承认,未来的收益可能不会带来任何令人愉快的惊喜。除非近期的中期状况有所改善,否则将继续在这些水平附近形成股价障碍。

You always need to take note of risks, for example - Modern Healthcare Technology Holdings has 4 warning signs we think you should be aware of.

你总是需要注意风险,例如,现代医疗技术控股公司有4个警告信号,我们认为你应该意识到。

If P/E ratios interest you, you may wish to see this free collection of other companies that have grown earnings strongly and trade on P/E's below 20x.

如果你对市盈率感兴趣,你可能想看看这个免费其他盈利增长强劲、市盈率低于20倍的公司。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有什么反馈吗?担心内容吗?保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
这篇由《华尔街日报》撰写的文章本质上是笼统的。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。简单地说,华尔街在提到的任何股票中都没有头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发